Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
For the treatment of osteoarthritis and dysmenorrhoea
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.